BioCure is currently seeking out-licensing opportunities for its versatile platform technologies.
Among BioCure's multiple platforms, GelSpray™ is by far its most versatile. GelSpray™ is a novel hydrogel based upon BioCure’s proprietary poly(vinyl alcohol) (PVA) technology. Developed primarily as a wound dressing, GelSpray™ is delivered as a liquid to the wound site, where the fast-cross linking reaction creates a highly cohesive and conformal dressing , closely approximating the wound bed. Where other commercially available dressings fail, GelSpray™effectively manages wound exudate, maintains high humidity, allows some gas exchange, provides thermal insulation, protects from secondary infection and is easily removed without re-injuring the wound site.
In addition to GelSpray™, BioCure is looking at the commercialization of itspolymeric vesicle technology,particularly in the areas of drug delivery and in-vitro diagnostics. BioCure is synthesizing their own block copolymers for the formation of vesicles and nanocontainers in the range of 80-800 nm. Molecules, such as membrane proteins, can be incorporated into the wall of the vesicles in order to allow diffusion of molecules. So called nanoreactors can be used for a prodrug therapy or as amplification schemes for in-vitro diagnostics.
Please contact us to learn more about these technologies and partnering opportunities.